Safety and efficacy data have started to provide a solid basis for building confidence in new and promising treatment modalities such as mesenchymal stem cells (MSCs).
- Closing Digital Gaps To Unlock The Potential Of The CGT Supply Chain
- Mapping Cell And Gene Therapy Processes: A Common Frame Of Reference For Scientists And Engineers
- C&G Therapy Manufacturing Automation: Making The Most Of Today’s Opportunities
- The Potential of In Vivo Gene Therapy in Rare Pediatric Diseases Like Mucopolysaccharidosis Type II
- Cell and Gene Therapies Are Driving Investment Opportunities
- Philadelphia’s Talent Pipeline Collaborative Readies Region For Cell And Gene Therapy Job Growth
- Future Delivery Models For ATMPs: Practical Considerations
- 2020 Gene Therapy Progress Wrap-Up
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Viral Clearance: The Basics On How To Conduct Effective Studies
Effective viral clearance studies remain one of the challenges facing manufacturers of biologics. These studies are an essential part of process validation and are critical to ensure drug safety. This article provides the basics of what you need to know when studying virus reduction of a chromatography step.
-
Subvisible Particulate Matter Testing
This application note demonstrates the capabilty of advanced, automated systems for subvisible particle testing in injections, ophthalmic solutions, and lipid emulsions.
-
Comparator Local Sourcing For Clinical Trials
This growing demand for comparators is causing many supply chain managers to explore available sourcing options. This paper examines the fundamentals of local sourcing, including the benefits and challenges of sourcing locally, and the circumstances under which local sourcing can be a sound decision. Recommendations are provided for avoiding common pitfalls in implementing a local sourcing strategy.
-
Gene Selection Using PrimePCR Plates And CFX Maestro Software
Reference gene selection and validation are very important for gene expression studies that involve different samples or experimental conditions and therefore are absolutely necessary before any further exploration. Read how PrimePCR Reference Gene Selection Panels provide an easy-to-use system with which to select appropriate reference genes.
-
A Model To Increase Yield In mAb Cell Culture Perfusion At Large Scale
As process intensification is adopted into large scale manufacturing, the responsibility of scale-down models to accurately represent the expanded operating space quickly follows.
-
Getting Your Investigational Drug Regulatory Ready
Here, we map out basic information to help you approach regulatory policies and offer helpful strategies to facilitate efficient regulatory review and drug approval.
-
Osmolality As A Concentration Measurement Method For Key Buffers In Bioprocessing
The manufacturing of biologics is a complex and costly process by which a protein is recovered and purified of contaminants to ultimately generate a drug product. This is accomplished through a chain of filtration and chromatography processes. This study was conducted to understand how osmolality can serve as a concentration measurement and how it compares to pH and conductivity measurements.
-
Single-Use Systems For Shipping Frozen Drug Materials – Every Component Counts
Integrated single-use freeze-thaw assemblies with reliable component parts, such as the connectors supplied by CPC, have become the primary implementation choice for achieving successful drug substance transfers between manufacturing facilities.
-
8 Ways Osmolality Tests Improve Cell & Gene Process Dev, Manufacturing
Cell and gene therapies have the potential to revolutionize incurable, debilitating, and often fatal diseases. This paper outlines eight emerging and novel uses for osmolality testing in advanced therapy production.
-
Multiplexing: Managing Risk With Proven, Single-Use Solutions
Instead of trying to make better predictions or erring on the side of overcapacity, developers and CDMOs should seek manufacturing flexibility.
NEWSLETTER ARCHIVE
- 04.01.21 -- Cell & Gene Best Of March
- 03.31.21 -- Powering Cell & Gene Therapy Innovation With Technology Disrupters
- 03.30.21 -- Medicare Braces For Expanded Use Of High-Cost CAR T-Cell Therapy
- 03.25.21 -- A Major Drilldown Into BioPhorum's CGT Process Maps
- 03.24.21 -- How To Select The Right Tool For Product-Process Data Management
- The Center For Breakthrough Medicines’ Newest Leaders Talk Advanced Therapy Development, Manufacturing
- Inside Repertoire Immune Medicines’ T Cell Recognition Of SARS-CoV-2
- Tevogen Bio, BioCentriq Team Up To Manufacture T-Cell Therapy For COVID-19
- Orchard Therapeutics’ CEO One Year In, Part 2
- Orchard Therapeutics’ CEO One Year In
CELL AND GENE LIVE
In this on-demand webinar Cell & Gene Chief Editor Erin Harris talks with Dr. Mark Gilbert, SVP of R&D at Acepodia, Thomas Lequertier, Head of Cell Therapy Manufacturing Unit at Celyad Oncology, and Luděk Sojka, Ph.D., Chief Technology Officer at SOTIO, about the innovations in manufacturing that can reduce both costs and risks.
Cell & Gene Live On-DemandCELL AND GENE CONTENT COLLECTIONS
Even though cell therapy and gene therapy are overlapping fields of biomedical research, there are differences between them that are germane to each. Cell therapy has challenges and risks all its own. For your reference, here are some of the latest articles that will help you better understand the benefits, risks, costs, and more associated with cell therapy.
More Content Collections